This is the authors' abstract. We don't add key points for this paper.
Metabolic diseases (MDs) are defined as the cluster of metabolic disorders that can lead to a broad spectrum of pathologies. The gut microbiota played a critical role in the development of MDs. Regulating gut microbiota through dietary intervention was widely used to reduce the risk of MDs. β-glucan as dietary fiber can improve the pathophysiological indicators and gut microbiota composition of MDs, resulting in the production of short-chain fatty acids, which improve gut health to alleviate MDs. This review updates the recent studies associated with the effects of β-glucan on the development of MDs, highlighting the role of gut microbiota in modulating MDs.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: